the KEEFEKTIVITASAN REMDESIVIR UNTUK TERAPI SARS-COV-2
Abstrak
Background : SARS-CoV 2 belongs to the coronaviridae family and the genus ?-CoV which has a single positive RNA chain with major structural proteins. namely Spike (S) which will bind to its receptor, Angiotensin Converting Enzyme 2 (ACE2). SARS-CoV2 has become a pandemic with a total number of cases worldwide reaching 1,777,666 people. Therapies used today are hydrocloroquin and macrolides. both work as immunomodulators. but hydrocloroquin has resistance. therefore we need therapy that has a target mechanism for other RNA virus molecules
Method : The writing is based on a journal review that is relevant to the topic to be discussed, the selected journal is a journal in the last 5 years. Based on the journals that have been collected and analyzed and compared between journals, 22 journals from a total of 30 journals are used. keywords used were ‘SARS-CoV-2, Hydroxychloroquine, azithromycin, and Remdesivir
Discussion: SARS-CoV-2 is a ?-coronavirus (CoV) that belongs to family Coronaviridae, subfamily Orthocoronavirinae, has a single strand positive RNA. Like SARS-CoV, this virus requires Angiotensin-Converting Enzyme 2 (ACE-2) receptor for its entry, found in the lower respiratory tract. The virus enters the cell, antigen presented to the Antigen Presenting Cells, causing cytokine storm, ARDS, and multiple organ dysfunction ends with death. To fight SARS-CoV-2, treatment still basis on other coronaviruses research, SARS and MERS. From earlier researches, a combination of hydroxychloroquine and azithromycin become the drug of choice. This combination can reduce replication also viral load, including one from these researches shows that 100% of the samples cured of SARS-CoV-2. Unfortunately, the mechanism behind these medications are unknown, so research is needed to find potent anti-SARS-CoV-2 medicines and work on viral RNA. In this literature, we focus on SARS-CoV-2 promising treatments such as Remdesivir, as an alternative for hydroxychloroquine and azithromycin.
Conclusion: Remdesivir has antiviral activity in vitro dan in vivo against viral RNA that cannot be done by Chloroquine.
##plugins.generic.usageStats.downloads##
Referensi
2. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
3. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal [Internet]. 2020;19(xxxx):1–7. Available from: https://doi.org/10.1016/j.jpha.2020.03.001.
4. Song W, Gui W, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14(8):1–19.
5. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med [Internet]. 2020;8(4):420–2. Available from: http://dx.doi.org/10.1016/S2213-2600(20)30076-X.
6. Daga MK, Kumar N, Aarthi J, Mawari G, Garg S, Rohatgi I. From SARS-CoV to Coronavirus Disease 2019 ( COVID-19 ) - A Brief Review. 2020;6(4):1–9.
7. Liu J, Cao R, Xu M, Wang Xi, Zhang H, Hu H, et al. Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, is Effective in Inhibiting SARS-CoV-2 Infection In Vitro. Cell Discovery. 2020; 6: 16.
8. Al-Bari AA. Chloroquine Analogues in Drug Discovery: New Directions of Uses, Mechanisms of Actions and Toxic Manifestations from Malaria to Multifarious Diseases. J Antimicrob Chemother. 2015; 70: 1608–1621.
9. Belizaire R, Unanue ER. Targeting Proteins to Distinct Subcellular Compartments Reveals Unique Requirements for MHC Class I and II Presentation. PNAS. Oktober 2009; 106(41): 17463-17468.
10. Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory Effects of Macrolides—a Systematic Review of the Underlying Mechanisms. Front Immunol. 2018; 9(302): 1-14.
11. Min JY, Jang YJ. Macrolide Therapy in Respiratory Viral Infections. Mediator of Inflammation. 2012; 649570: 1-9.
12. Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. Preprints. 20 Maret 2020. Available from: https://doi.org/10.20944/preprints202003.0302.v1
13. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a Potent Inhibitor of SARS Coronavirus Infection and Spread. Virology Journal. 2005; 2(69): 1-10.
14. Keyaerys E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice. Antimicrob Agents Chemother. Agustus 2009; 53(8): 3416-3421.
15. Liang R, Wang L, Zhang N, Deng X, Su M, Su Y, et al. Development of Small-Molecule MERS-CoV Inhibitor. Viruses. Desember 2018; 10(12): 721.
16. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. Published 1 Maret 2020. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105938
17. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Published 9 Maret 2020. Available from: https://doi.org/10.1093/cid/ciaa237
18. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-label Non-randomized Clinical Trial. Int J Antimicrobial Agents. Published 20 Maret 2020. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105949.
19. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In Vitro Testing of Hydroxychloroquine and Azithromycin on SARS-CoV-2 Shows Synergistic Effect. Mediterranee Infection. Published 2 April 2020. Available from: https://www.mediterranee-infection.com/wp-content/uploads/2020/03/La-Scola-et-al-V1.pdf
20. Rosa SGV dan Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. RevPanam Salud Publica. 2020; 44:e40. Doi.org/10.26633/RPSP.2020.40.
21. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J. The use of anti-inflamatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologist from china. 2020. doi: 10.1016/j.clim.2020.108393
22. Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-New Coronavirus (SARS-COV2): A review and perspective. 2020. 16(10): 1708–1717. doi: 10.7150/ijbs.45538.
